<code id='0C3F2EF9EE'></code><style id='0C3F2EF9EE'></style>
    • <acronym id='0C3F2EF9EE'></acronym>
      <center id='0C3F2EF9EE'><center id='0C3F2EF9EE'><tfoot id='0C3F2EF9EE'></tfoot></center><abbr id='0C3F2EF9EE'><dir id='0C3F2EF9EE'><tfoot id='0C3F2EF9EE'></tfoot><noframes id='0C3F2EF9EE'>

    • <optgroup id='0C3F2EF9EE'><strike id='0C3F2EF9EE'><sup id='0C3F2EF9EE'></sup></strike><code id='0C3F2EF9EE'></code></optgroup>
        1. <b id='0C3F2EF9EE'><label id='0C3F2EF9EE'><select id='0C3F2EF9EE'><dt id='0C3F2EF9EE'><span id='0C3F2EF9EE'></span></dt></select></label></b><u id='0C3F2EF9EE'></u>
          <i id='0C3F2EF9EE'><strike id='0C3F2EF9EE'><tt id='0C3F2EF9EE'><pre id='0C3F2EF9EE'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:comprehensive    Page View:4
          John Thune raises one hand while speaking to the press at the Capitol 2024 — politics coverage from STAT
          Sen. John Thune is one of a group of lawmakers that is working on 340B reform legislation. BRENDAN SMIALOWSKI/AFP via Getty Images

          WASHINGTON — A bipartisan group of senators released a draft of legislation to resolve controversial disputes in the 340B drug discount program, according to documents obtained by STAT.

          The drug discount program, which was designed to support providers that serve low-income patients, has been increasingly contentious as it’s grown in recent years. The draft legislation makes a number of changes to address some of the most controversial points, including its rules over so-called “contract pharmacies” and which subsidiaries can qualify for discounts.

          advertisement

          The draft would also require more oversight, and it would give the Health Resources and Services Administration more money to do it with a new user fee program. Providers would pay HRSA up to 0.1% of the savings it receives from the program.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more
          CRISPR gene editing developments we’re watching in 2024
          CRISPR gene editing developments we’re watching in 2024

          ChristineKao/STATLifeintheCRISPRlanetendstomoveatlightningspeed.Thisyearsawthefirst-everapprovalofam

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Annovis Bio delivers candor, but not confidence, on Parkinson’s study

          MollyFerguson/STATAnnovisBiohadmybiotechbull%^&!meterrunningredafteritmadealatechangetothedesign